Human Anti-EGFR Recombinant Antibody (clone C225) (CAT#: PABL-462)

Recombinant Human Antibody (C225) is capable of binding to EGFR, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-EGFR mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-EGFR proteins mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Inhibition of VEGF (A), IL-8 (A), and bFGF (B) steady-state mRNA expression by C225 mAb in vitro.

Figure 1 Inhibition of VEGF (A), IL-8 (A), and bFGF (B) steady-state mRNA expression by C225 mAb in vitro.

Cells were cultured in the presence of or absence of MAb C225. mRNA was extracted after 48 h of treatment and analyzed by Northern blotting. Using image densitometry, the mRNA expression of untreated cells was assumed to be 100% of potential expression for these cells. Treatment with C225 down-regulated VEGF, IL-8, and bFGF mRNA expression in a dose-dependent fashion. β-actin served as a control for loading (exposure, 30 min).

Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., ... & Dinney, C. P. (1999). Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research, 5(2), 257-264.

Figure 2 Immunohistochemical staining of MAb C225-treated human TCC tumors growing in the bladders of athymic nude mice.

Figure 2 Immunohistochemical staining of MAb C225-treated human TCC tumors growing in the bladders of athymic nude mice.

MAb C225-treated tumors (after 3 weeks and 5 weeks of therapy) and control tumors were stained with CD31 antibodies directed against mouse endothelial cells (A–C). Note the increased vessel density in the control tumors (A) and the 3-week C225-treated tumors (B) compared with that of the 5-week C225-treated specimen (C). Immunostaining for VEGF (D–F), IL-8 (G–I), and bFGF (J–L) is higher in the control tumors (D, G, and J) than in the MAb C225-treated specimens (E, F, H, I, K, and L) at 3 weeks and 5 weeks. Note that the down-regulation of VEGF, IL-8, and bFGF precedes the inhibition of angiogenesis.

Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., ... & Dinney, C. P. (1999). Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research, 5(2), 257-264.


Specifications

  • Immunogen
  • Human epidermal growth factor receptor
  • Host Species
  • Human
  • Type
  • Human IgG
  • Specificity
  • Human EGFR
  • Species Reactivity
  • Human
  • Clone
  • C225
  • Applications
  • FC

Product Property

  • Purity
  • >95% as determined by SDS-PAGE and HPLC analysis
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog;

Related Resources

  • Related Diseases
  • Related Signaling Pathways

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone C225"

See other products for "EGFR"

Human Antibody

CAT Product Name Application Type
TAB-020 Anti-Human EGFR Recombinant Antibody (Panitumumab) ELISA, IP, FC, FuncS, Neut, IF, ICC IgG2 - kappa
TAB-040 Anti-Human EGFR Recombinant Antibody (Zalutumumab) ELISA, FC, IP, FuncS, IF, Neut, ICC IgG1 - kappa
TAB-119 Anti-Human EGFR Recombinant Antibody (Necitumumab) FC, IP, ELISA, Neut, FuncS, IF, WB IgG1 - kappa
TAB-278MZ-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-278MZ-F(E)) ELISA, WB Human Fab
PABX-053 Recombinant Human Anti-EGFR Antibody (DL11) WB, ELISA, FuncS IgG

Humanized Antibody

Chimeric Antibody

CAT Product Name Application Type
TAB-0225CL-F(E) Human Anti-EGFR Recombinant Antibody; Fab Fragment (TAB-0225CL-F(E)) Block, Inhib, FuncS, Apop, In vivo Chimeric (Mouse/Human) Fab
TAB-272MZ Human Anti-EGFR Recombinant Antibody (TAB-272MZ) FuncS Chimeric (mouse/human) IgG
TAB-302MZ Human Anti-EGFR Recombinant Antibody (TAB-302MZ) ELISA Chimeric (mouse/human) IgG1
TAB-308MZ Human Anti-EGFR Recombinant Antibody (TAB-308MZ) FuncS Chimeric antibody (mouse/human)
TAB-302MZ-S(P) Mouse Anti-EGFR Recombinant Antibody; scFv Fragment (TAB-302MZ-S(P)) ELISA Mouse scFv

Fc Glycosylation

High-mannose Glycoform

CAT Product Name Application Type
Gly-055LC-1 Recombinant Anti-Human EGFR Antibody (Fc glycosylation/High-mannose glycosylated) ELISA Chimeric antibody (mouse/human)

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-167LC Recombinant Anti-Human EGFR Antibody (Non-glycosylated) ELISA Human antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0183MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody
BRD-0668MZ Chicken Anti-EGFR Polyclonal IgY WB Chicken antibody

Neutralizing Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-165 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Matuzumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-464CQ Afuco™ Anti-EGFR ADCC Recombinant Antibody (Tomuzotuximab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-003 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Cetuximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-040 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Zalutumumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody
AFC-TAB-119 Afuco™ Anti-EGFR ADCC Recombinant Antibody (Necitumumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABL-462. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare